Antifungal Drugs in Treatment of Onychomycosis

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03171584
Collaborator
(none)
60
3
28

Study Details

Study Description

Brief Summary

Onychomycosis refers to the fungal infection of the fingernails or toenails, caused by dermatophytes, yeast and non-dermatophyte molds that lead to distortion, discoloration, thickening and detachment from the nail bed

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

Onychomycosis accounts for up to 30% of all superficial infections of skin and constitutes about a half of all nail abnormalities; affecting approximately 5% of population worldwide

The prevalence of onychomycosis is determined by age, social class, occupation, climate, living environment and frequency of travel Despite being common dermatological presentation, the exact prevalence of onychomycosis remains largely unknown.

Toenails are more commonly affected than fingernails due to slower rate of growth of the former, reduced blood supply and usual confinement in dark moist environments The infection is more common in adult males (particularly elderly > 60 yrs of age), diabetics, immunocompromised individuals (e.g. HIV positive), individuals with peripheral vascular (arterial) disease, previous tineapedis infection, history of trauma to the nail, or those with a family history of onychomycosis Dermatophytes whether pathogenic or saprophytes are the commonest causative nail invaders Dermatophytic onychomycosis can be divided into four major clinical types on the basis of their presenting clinical features; distal and lateral subungualonychomycosis (DLSO), proximal subungualonychomycosis (PSO), white superficial onychomycosis (WSO) and total dystrophic onychomycosis (TDO) , Among these,distal and lateral subungualonychomycosis( DLSO) is the most common form.

Clinical diagnosis by physical examination alone can be inaccurate as many non infectious conditions that mimic onychomycosis like lichen planus, psoriasis need to be ruled out . Various laboratory techniques have been used to accurately diagnose onychomycosis, with microscopy by KOH and fungal culture being the most frequently used The histopathology of nail clippings can be utilized for diagnosing onychomycosis, with periodic acid-Schiff (PAS) stain that allows easy visualization of fungal hyphae . Digital dermoscopy, also called onychoscopy, is an easy and quick procedure that allows differential diagnosis of onychomycosis from the common nail dystrophies.

Dystrophic nails can be a social impediment causing significant embarrassment that affects patient's self-esteem. In addition, thickened nails can be painful, interfere with the function of the nail unit and may cause discomfort in walking, standing and exercising.

Though initially presenting as a cosmetic problem, it can eventually lead to permanent disfigurement of the nails and serve as a source of other fungal infections . Due to these significant effects specific questionnaire was designed and validated to assess quality of life in patients with onychomycosis

Treatment is chosen depending on the modality of nail invasion, fungus species and the number of affected nails. Oral treatments are often limited by drug interactions, while topical antifungal lacquers have less efficacy . Surgery or nail debridement is another invasive treatment option in limited resistant cases .

The use of griseofulvin and ketoconazole is problematic, as there are typically high relapse rates of 50-85%. In addition, treatment must be continued for a long duration with risky systemic side effects.

Fluconazole, itraconazole and terbinafine are relatively safe antifungal drugs that have been widely used with improved treatment success, producing a mycological cure in more than 90% of fingernail infections and in about 80% of toenail infections

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis
Anticipated Study Start Date :
Jul 1, 2017
Anticipated Primary Completion Date :
Jun 1, 2019
Anticipated Study Completion Date :
Nov 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Terbinafine group

Arm (1) will receive Terbinafine (250mg/day for 6 weeks).

Drug: Terbinafine
oral antifungal drugs
Other Names:
  • Fluconazole
  • Itraconazole
  • Experimental: Fluconazole group

    Arm (2) will receive Fluconazole (300mg once weekly for 3monthes).

    Drug: Terbinafine
    oral antifungal drugs
    Other Names:
  • Fluconazole
  • Itraconazole
  • Experimental: Itraconazole group

    Arm (3) will receive Itraconazole (400mg/day for one week per month followed by 3 free weeks ,, 2 pulses for finger nail)

    Drug: Terbinafine
    oral antifungal drugs
    Other Names:
  • Fluconazole
  • Itraconazole
  • Outcome Measures

    Primary Outcome Measures

    1. cure rate of patients [one year]

      Percentage of patients with complete cure in every group

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with finger nail onychomycosis of different sex and age.
    Exclusion Criteria:
    1. Patients taking immunosuppressive drugs or drugs affecting nail colour or growth.

    2. Patients with previous trauma to the nails.

    3. Pregnant and lactating women.

    4. Patients with 20 nail dystrophy.

    5. Patients with keratinization disorders as psoriasis and chronic medical or cutaneous diseases.

    6. Patients with chronic medical or cutaneous diseases that may affect quality of life.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    AMLadeed, A comparative Study of Systemic antifungal drugs used in treatment of onychomycosis, Assiut University
    ClinicalTrials.gov Identifier:
    NCT03171584
    Other Study ID Numbers:
    • oncho
    First Posted:
    May 31, 2017
    Last Update Posted:
    May 31, 2017
    Last Verified:
    May 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 31, 2017